The exact ingredients for Trelegy Ellipta are not publicly disclosed by the manufacturer for proprietary reasons. However, Trelegy Ellipta is a combination inhaler containing three active medications used to treat chronic obstructive pulmonary disease (COPD) and asthma.
What medications are in Trelegy Ellipta?
Trelegy Ellipta combines fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1].
How do these medications work together?
The inhaled corticosteroid, fluticasone furoate, reduces inflammation in the airways. Umeclidinium, a LAMA, relaxes the muscles around the airways, making it easier to breathe. Vilanterol, a LABA, also helps to relax airway muscles and keeps them open for 24 hours [1]. This triple combination addresses the different mechanisms contributing to airflow limitation in COPD and asthma.
What are the specific inactive ingredients in Trelegy?
While the active ingredients are known, the specific inactive ingredients (excipients) used in Trelegy Ellipta are not detailed in readily available public documentation. These inactive ingredients are generally considered safe and serve to formulate the drug product, for example, as fillers or binders for the powder in the inhaler.
Where can I find detailed prescribing information for Trelegy?
Detailed prescribing information, including known side effects and warnings, can be found in the official prescribing information provided by the manufacturer, GlaxoSmithKline. This information is typically available through regulatory agency websites or medical information portals. DrugPatentWatch.com may also have information regarding patent exclusivity for Trelegy [2].
Sources:
1. https://www.trelegy.com/
2. https://drugpatentwatch.com/